Maravai LifeSciences Holdings Inc (MRVI) concluded trading on Thursday at a closing price of $3.95, with 4.84 million shares of worth about $19.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -57.25% during that period and on February 20, 2025 the price saw a loss of about -3.19%. Currently the company’s common shares owned by public are about 141.59M shares, out of which, 117.86M shares are available for trading.
Stock saw a price change of -7.28% in past 5 days and over the past one month there was a price change of -24.47%. Year-to-date (YTD), MRVI shares are showing a performance of -27.52% which decreased to -25.61% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.04 but also hit the highest price of $11.56 during that period. The average intraday trading volume for Maravai LifeSciences Holdings Inc shares is 1.84 million. The stock is currently trading -16.67% below its 20-day simple moving average (SMA20), while that difference is down -23.06% for SMA50 and it goes to -46.53% lower than SMA200.
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) currently have 141.59M outstanding shares and institutions hold larger chunk of about 87.07% of that.
The stock has a current market capitalization of $997.48M and its 3Y-monthly beta is at -0.09. It has posted earnings per share of -$1.65 in the same period. It has Quick Ratio of 9.94 while making debt-to-equity ratio of 1.63. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRVI, volatility over the week remained 6.74% while standing at 7.78% over the month.
Stock’s fiscal year EPS is expected to drop by -361.30% while it is estimated to increase by 16.59% in next year.
Coverage by Goldman stated Maravai LifeSciences Holdings Inc (MRVI) stock as a Sell in their note to investors on December 05, 2024, suggesting a price target of $4.25 for the stock. Stock get an Overweight rating from Wells Fargo on August 28, 2024.
